Recently, a new study has brought attention to a significant benefit of weight loss drugs beyond just losing weight.
These medications have gained substantial popularity over the past few years, with various reports and studies discussing their potential risks and warnings.
Nonetheless, a recent investigation has pointed out a critical advantage of GLP-1 agonist drugs, even if significant weight loss isn’t achieved.
As indicated by their name, GLP-1 agonists are a form of treatment that imitates the hormone, GLP-1.
This hormone regulates blood sugar levels and can help control appetite, making these drugs suitable for treating type 2 diabetes and for weight loss purposes.
GLP-1 has been available as a weekly injectable pen in recent years.
New findings regarding these GLP-1 medications were presented at the European Society of Cardiology annual conference in August, revealing that these drugs might offer significant cardiovascular benefits.
Researchers from Mass General Brigham in the US discovered that weight loss medications could decrease the risk of early death or hospitalization for individuals with heart conditions by up to 58%.
The researchers examined data from over 90,000 heart failure patients who were both obese and diagnosed with type 2 diabetes.
The study found that participants using semaglutide, the active component in Ozempic, Wegovy, and other GLP-1 medications, had a 42% lower risk of hospitalization or premature death.
A Mail Online report mentions that British researchers have observed similar findings, concluding that these drugs could improve heart health regardless of the extent of weight loss.